The therapeutic relevance of a BRCA2 mutation in a patient with recurrent thymoma: a case report.

ABSTRACT:

Background

Thymomas are characterized by a low tumor mutation burden and a paucity of actionable mutations. Clinical behavior can vary from relatively indolent to very aggressive and impact survival. Platinum-based chemotherapy is the primary treatment modality for inoperable disease and is palliative in intent. Patients with advanced thymoma frequently experience disease recurrence after frontline therapy. Treatment options for relapsed thymoma are relatively limited. A case of recurrent thymoma harboring a breast cancer gene 2 (BRCA2) mutation was presented for multidisciplinary discussion at the International Thymic Malignancy Interest Group (ITMIG) Tumor Board meeting.

Case description

A 63-year-old female presented with Tumor Node Metastasis (TNM) stage I, World

SUBMITTER: Sigurdson S 

PROVIDER: S-EPMC9792822 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature